ATE274922T1 - Methoden zur krebskontrolle und -behandlung - Google Patents

Methoden zur krebskontrolle und -behandlung

Info

Publication number
ATE274922T1
ATE274922T1 AT96900189T AT96900189T ATE274922T1 AT E274922 T1 ATE274922 T1 AT E274922T1 AT 96900189 T AT96900189 T AT 96900189T AT 96900189 T AT96900189 T AT 96900189T AT E274922 T1 ATE274922 T1 AT E274922T1
Authority
AT
Austria
Prior art keywords
treatment
methods
cancer control
expression
control
Prior art date
Application number
AT96900189T
Other languages
English (en)
Inventor
Kei Fujinaga
Koichi Yoshida
Fumihiro Higashino
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of ATE274922T1 publication Critical patent/ATE274922T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
AT96900189T 1995-02-08 1996-01-09 Methoden zur krebskontrolle und -behandlung ATE274922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017395 1995-02-08
PCT/JP1996/000016 WO1996024379A1 (fr) 1995-02-08 1996-01-09 Traitement du cancer

Publications (1)

Publication Number Publication Date
ATE274922T1 true ATE274922T1 (de) 2004-09-15

Family

ID=12019792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96900189T ATE274922T1 (de) 1995-02-08 1996-01-09 Methoden zur krebskontrolle und -behandlung

Country Status (7)

Country Link
US (3) US6096542A (de)
EP (2) EP1484067A3 (de)
JP (1) JP3844501B2 (de)
AT (1) ATE274922T1 (de)
AU (1) AU4357396A (de)
DE (1) DE69633272T2 (de)
WO (1) WO1996024379A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1084969A (ja) * 1996-09-19 1998-04-07 Chemo Sero Therapeut Res Inst ヘモフィルス・パラガリナルム由来新規ポリペプチド及びその製法
US6248351B1 (en) 1997-01-10 2001-06-19 Board Of Regents,The University Of Texas System Human PEA3 is a tumor suppressor for cancer cells
US5922688A (en) * 1997-01-10 1999-07-13 Board Of Regents, The University Of Texas System PEA3 is a tumor suppressor
AU2001243985A1 (en) * 2000-03-20 2001-10-03 Mcgill University Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion
WO2002064165A1 (fr) * 2001-02-13 2002-08-22 Hisamitsu Pharmaceutical Co., Inc. Inhibiteurs de la proliferation cellulaire comprenant un facteur de transcription ets ou un gene codant ce dernier
EP1573024A4 (de) 2001-04-10 2007-08-29 Agensys Inc Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR102411781B1 (ko) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
GB201410686D0 (en) * 2014-06-16 2014-07-30 Immunocore Ltd & Adaptimmune Ltd Peptides
IL298227B2 (en) 2016-06-01 2024-09-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
EP3678695A1 (de) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomale formulierungen enthaltend saponin und verwendungsverfahren
JP2022532944A (ja) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05328975A (ja) * 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
AU4769893A (en) * 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
DE69333921T2 (de) * 1992-12-31 2006-08-10 Dana-Farber Cancer Institute, Inc., Boston "enhancer" sequenz zur modulation der expression in epithelialzellen
DE69431564D1 (de) * 1993-11-12 2002-11-21 Ribozyme Pharm Inc Reagenz zur behandlung von arthritischen zustaenden
US5552390A (en) * 1993-12-09 1996-09-03 The Board Of Regents Of The University Of Nebraska Phosphorothioate inhibitors of metastatic breast cancer
AU4412096A (en) * 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6566063B1 (en) * 1999-05-14 2003-05-20 Chiron Corporation Methods for determining metastatic potential of breast cancer cells by detecting GSEF gene product expression

Also Published As

Publication number Publication date
US20030087862A1 (en) 2003-05-08
DE69633272D1 (de) 2004-10-07
US7070931B2 (en) 2006-07-04
US6528310B1 (en) 2003-03-04
EP1484067A2 (de) 2004-12-08
DE69633272T2 (de) 2005-09-08
EP0808630B1 (de) 2004-09-01
AU4357396A (en) 1996-08-27
EP1484067A3 (de) 2005-03-02
JP3844501B2 (ja) 2006-11-15
EP0808630A1 (de) 1997-11-26
US6096542A (en) 2000-08-01
EP0808630A4 (de) 2000-09-27
WO1996024379A1 (fr) 1996-08-15

Similar Documents

Publication Publication Date Title
ATE274922T1 (de) Methoden zur krebskontrolle und -behandlung
TR199701462T1 (xx) DNA Dizisi ve bununla kodlanm�� meme'ye �zel g���s kanseri proteini.
AU7074698A (en) Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease
DE59609222D1 (de) Amperometrischer Biosensor
ATE317435T1 (de) Prostataspezifisches membranes antigen und seine anwendungen
ATE433498T1 (de) Detektion von neoplasien durch speichelanalyse
DE69332642D1 (de) Methoden zur detektion von mikrometastasen bei prostata-krebs
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
FI970445A (fi) Hydrofobisten polypeptidien tuotanto bakteerien avulla
ES2117855T3 (es) Proteina del ciclo celular de mamifero.
DE19622397B8 (de) Elektrische Vorrichtung als Sauerstoffkonzentrationssensor
NL300271I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
AU5996996A (en) Al/fe-treatment of a protein solution, followed by membrane concentration
CY1108288T1 (el) Αντισωματα για το αντιγονο κυτταρων langerhans θηλαστικων και χρησεις τους
TR200200667T2 (tr) Leu-hirudinin E.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları.
ATE225859T1 (de) Nachweis von antibiotikumresistenzen in mikroorganismen
DE69608683D1 (de) Analytisches und therapeutisches mittel
ATE122723T1 (de) Retinoblastoma-genprodukt-antikörper und deren verwendungen.
TR199901862T2 (xx) Yeni Bile�ikler.
GB2313912B (en) Thin film technology for the fabrication of sensitive, robust biosensors
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.
SE9603344D0 (sv) Method and apparatus for detecting substances
EP0850249A4 (de) Neues verfahren zum nachweis von cryptosporidium
FR2667079B1 (fr) Procedes, oligonucleotides amorces et oligonucleotides sondes pour la detection de bacteries pathogenes de la cavite buccale.
FR2741087B1 (fr) Complexe proteique dodecaedrique adenoviral, procede de preparation, composition le contenant et ses applications

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties